A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial is in Phase 1 and is testing how two drugs — UIC202601 and UIC202602 — interact with each other in the body, so it's focused on pharmacokinetics and safety rather than treating my hypertension or dyslipidemia — does that mean I wouldn't be receiving a proven treatment for my condition if I enrolled?
2. 2Since this is an early-phase study in healthy volunteers that is primarily measuring drug levels in the blood rather than clinical outcomes, what does that tell us about how much is still unknown regarding the safety of these two drugs when taken together?
3. 3The trial has two arms and two periods, which likely means participants receive the drugs in different sequences or combinations — can you help me understand what that would actually involve day-to-day, and whether the time commitment would be realistic for my situation?
4. 4Given that my conditions — hypertension and dyslipidemia — typically have well-established standard treatments available, would it make more sense to prioritize those proven options first before considering participation in an early drug-interaction study like this?
5. 5If I were to discuss this trial with my care team, what specific health criteria or medication history might make me a good or poor fit for a study that is enrolling healthy volunteers, especially since I'm already managing hypertension and dyslipidemia?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.